^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MET amplification

    i
    Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
    Entrez ID:
    4233
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    11ms
    TPS9149: Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) Monotherapy in Patients With Previously Untreated MET Amplified Locally Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer (NSQ NSCLC). MET-specialist ADC for MET Amp. #ASCO23 #LCSM (@HHorinouchi)
    Clinical • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    telisotuzumab vedotin (ABBV-399)
    11ms
    Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer [2023] Minne et al. #ASCO23 Abst 8553, Poster 180 https://t.co/ADGszHjzgr #lcsm #PrecisionMedicine @UWCarbone @TempusLabs (@mtmdphd)
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation
    11ms
    In #met amplification and fusion there is a disparity between #ngs testing with DNA or RNA. Pay attention to what you are getting says ⁦@DavidRSpigel⁩ ⁦@DrNeilLove⁩ #rtp #lungcancer ⁦@SarahCannonDocs⁩ ⁦@McKesson⁩ ⁦@ASCO⁩ #2023 already have blisters! (@donnashort)
    Next-generation sequencing
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    11ms
    When #MET amplification seen with resistance to #ALK inhibitors in NSCLC, is adding a MET TKI effective? Report led by Dr. @IbiayiMD @JTOonline #JTOCRR describes responses in 5 of 12 pts. More potent MET TKIs seem preferable. Safe but need to monitor tox. https://t.co/4qUcQPgtr9 (@StephenVLiu)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    11ms
    Report of 20 pts w/ #EGFR NSCLC + #MET amplification-mediated resistance to osimertinib in #JTOCRR from Dr. @LeXiuning & team. Adding MET TKI had RR 35%, median time on treatment 27m, 3 cases of pneumonitis. Resistance included MET D1246H, EGFR C797S. https://t.co/KJNnA1NV6r (@StephenVLiu)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • EGFR C797S
    |
    Tagrisso (osimertinib)
    11ms
    #ASCO23 @ASCO Abs#9021 Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification #INSIGHT2 ➡️122 pts received tepo + osi ➡️98 pts w/ FISH METAmp: ORR 43.9% ➡️31 pts with METamp by LBx: ORR 51.6% Poster Discussion @JoelNealMD @OncoAlert @EGFRResisters (@CharuAggarwalMD)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • MET mutation
    |
    Tagrisso (osimertinib) • Tepmetko (tepotinib)
    12ms
    Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer [2023] Minne et al. #ASCO23 Abst 8553, Poster 180 https://t.co/ADGszHjzgr #lcsm #PrecisionMedicine @UWCarbone @TempusLabs (@mtmdphd)
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation
    12ms
    Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer [2023] Minne et al. #ASCO23 Abst 8553, Poster 180 https://t.co/ADGszHjzgr #lcsm #PrecisionMedicine @UWCarbone @TempusLabs (@mtmdphd)
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation
    almost1year
    MET-specialist ADC in MET amplification: Preliminary Efficacy of Telisotuzumab Vedotin Treatment in the 2L/3L Setting in MET Gene Amplified, c-Met Protein Overexpressing, Non-squamous, NSCLC: Retrospective Analysis of LUMINOSITY by Dr. Ross Camidge. #AACR23 #LCSM (@HHorinouchi)
    Retrospective data
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET overexpression
    |
    telisotuzumab vedotin (ABBV-399)
    almost1year
    #ASCO23 TPS9149: Phase 2 study of telisotuzumab vedotin (Teliso-V) monotherapy in pts with previously untreated MET-amplified locally advanced/metastatic non-squamous non-small cell lung cancer. Check a MET-specialist ADC. See you @McCormick_Place @ASCO https://t.co/JnTtA9xH0Q (@HHorinouchi)
    Clinical • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    telisotuzumab vedotin (ABBV-399)
    1year
    #CedarsSinaiCancer at #AACR23. Dr. Inderjit Mehmi @Mi_onc & Dr. Kristopher Wentzel are co-authors on “#Crizotinib in patients with solid #tumors with MET amplification or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study” @CedarsSinaiMed (@CSCancerCenter)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    Xalkori (crizotinib)
    1year
    Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis https://t.co/gqqy7M0Wb4 (@AndresFCardonaZ)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • MET mutation
    |
    gefitinib • Tepmetko (tepotinib)
    1year
    Dr. Paul Paik explains how to navigate #MET in managing NSCLC. We have capmatinib and tepotinib approved for METex14 mutations - effective (but watch for toxicity). In the future - MET amplification and MET overexpression (IHC) likely to be relevant! #TexasLung23 (@StephenVLiu)
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET overexpression • MET amplification + MET overexpression
    |
    Tepmetko (tepotinib) • Tabrecta (capmatinib)
    1year
    🩸🧬 Analysis of acquired resistance to osimertinib in EGFR-mutated advanced NSCLC pts from the AURA3 trial: 50% undetectable plasma EGFR T790M, 19% have >1 resistance-mechanism: MET amplification (14/78, 18%) and EGFR C797X mutation (14/78, 18%). #LCSM https://t.co/r7V1qLfr4C (@Tony_Calles)
    Clinical • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • EGFR T790M
    |
    Tagrisso (osimertinib)
    1year
    We do see a number of our #ALK #lungcancer patient community with MET amplification and some disparities in treatment options depending on the country you live in. Great to see this studied. Thanks Drs @MandySakamoto & @TejasPatilMD. #ResearchSavesLives. #LCSM (@Yvonne_Diaz_)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    1year
    Agree! But we need to be careful to fact check everything it says. I tried to ask it to write an appeal letter for crizotinib in met amplified treatment-refractory GEJ AdenoCA. Couldn’t find the citations it listed. It finally apologized for making up references! 😂 (@ranj585)
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    Xalkori (crizotinib)
    over1year
    @KoheiShitara presenting ctDNA-guided subgroup analysis of PARADIGM; ctDNA guided negative hyperselection markers KRAS, NRAS, BRAF (V600E), PTEN, EGFR (ECD), HER2 and MET amplifications, ALK, RET, or NTRK1 fusions trumped sidedness in response to anti-EGFR benefit #GI23 (@MadhuEluri)
    Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    BRAF V600E • BRAF V600 • NTRK1 fusion • MET amplification • ALK amplification
    over1year
    Tepotinib provided clinically meaningful activity with durable responses in patients with #NSCLC & MET amplification, as detected by ctDNA, according to updated and exploratory findings from cohort B of the VISION trial. #lcsm | @MDAndersonNews @LeXiuning https://t.co/e8kHFjco4Y (@TargetedOnc)
    Clinical • Circulating tumor DNA
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    Tepmetko (tepotinib)
    over1year
    Tepotinib plus osimertinib is a promising combination in patients with osimertinib-pretreated, EGFR-mutated, MET amplified non­–small cell lung cancer. @JulienMazieres @myESMO #lcsm #ESMO2022 https://t.co/9qB70fm09t (@OncLive)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • MET mutation
    |
    Tagrisso (osimertinib) • Tepmetko (tepotinib)
    over1year
    Very helpful narrative review of #MET and its role in NSCLC @JTOonline. Covers approved and emerging agents. With MET, need to distinguish #METex14 mutations, MET amplification, and MET overexpression - as implications of each are quite different. #LCSM https://t.co/i6BZG8L7vT (@StephenVLiu)
    Review
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET overexpression • MET mutation
    over1year
    Final Phase Ib TATTON: Osimertinib+ Savolitinib to Overcome Acquired MET-Mediated Resistance in EGFR Mutated MET-Amplified NSCLC. MET copy-number ≥10 and EGFRm circulating tumor DNA clearance predict better outcomes. #LCSM https://t.co/9O4k9BeqMw (@Tony_Calles)
    Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • MET mutation
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib)
    over1year
    Dr. @LeXiuning presents response to tepotinib by ctDNA biomarkers in NSCLC with #MET amplification on liquid biopsy at #NACLC22. Encouraging activity but benefit seemed greater if amplification was focal. Low ctDNA and early molecular response had better outcomes. (@StephenVLiu)
    Liquid biopsy • Circulating tumor DNA
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    Tepmetko (tepotinib)
    over1year
    Excited to share my graduate student's work - "MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC". Notable that MET gene amp occurred via ecDNA. https://t.co/fXYlX8Xcbl @CUCancerCenter @ros1cancer (@rdoebele)
    MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    MET amplification
    |
    Rozlytrek (entrectinib)
    over1year
    BEACON translational analyses shared by @skopetz @myESMO: subclonal MAPK pathway activation with multiple acquired alterations (RAS/BRAF mutations, MET amplification…) as the main escape mechanism to BRAF/EGFR+/-MEK inhibition in BRAF V600 mutated mCRC (@malkadav)
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • BRAF mutation • BRAF V600 • MET amplification • RAS mutation • MET mutation • BRAF amplification
    over1year
    Phenomenal data from osi+tepotinib for osi-resistant met-amplified EGFR mut NSCLC by ⁦@JulienMazieres⁩ #esmo22 #lcsm (@bpiperdi)
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    Tepmetko (tepotinib)
    over1year
    C797S resistant mutation occurs in 12.5% of patients treated with first line osimertinib for EGFR mut NSCLC. Mostly appears after 1 yr of osi (MET amplification is predominant the first year). Population eligible to 4th gen EGFR inhibitors targeting C797S is limited. #WCLC2022 (@BenjaminBesseMD)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • EGFR C797S
    |
    Tagrisso (osimertinib)
    2years
    .@JoelNealMD, of @StanfordMed, discusses the emergence of targets such as HER2 exon 20 insertions and amplification, MET amplification, and NRG1 fusions. #lcsm https://t.co/fKVdC9CeCs (@OncLive)
    HER-2 (Human epidermal growth factor receptor 2) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRG1 (Neuregulin 1)
    |
    HER-2 amplification • MET amplification • HER-2 exon 20 insertion • NRG1 fusion • HER-2 exon 20 mutation • NRG1 amplification • NRG1 fusion
    2years
    I have a lady who has early stage lung cancer adeno, that is a surgical candidate but the surgeon requesting neoadjuvant chemo to improve resectability. PDL1 is 100 percent and she also has MET amplification 19 copies. Any thoughts and what would you do? This is to everyone (@andrea20372113)
    Clinical
    |
    PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    2years
    3 De-novo MeT amplification in NSCLC adeno ca / All cases are primary resistant for chemotherapy-+IO. @BostonGenomics @BenWestphalen @Dr_R_Kurzrock @wolfjurgen1981 @LeciaSequist @TonyMok9 @geoff_oxnard @christine_lovly @StephenVLiu @drgandara @ (@UmutDisel)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    2years
    #MET amplification is an emerging target both as a driver and as a mechanism of resistance. Best described in #EGFR mutant NSCLC but mediates resistance in many other driver-positive settings. Great review by Dr. @LeXiuning at #TTLC22. #LCSM (@StephenVLiu)
    Review
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification
    2years
    Was there also a subset analysis on Brain Met as we know they tend to have Met amplified (@ravi0273)
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    over2years
    Can we target #MET amplification? Dr. @alexdrilon explains at #PTTO2021. Key is in defining what relevant amplification is. Various methods - each with their own challenges. MET TKI efficacy linked to degree of amplification across studies. #LCSM (@StephenVLiu)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    over2years
    "MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING" Link to the article: https://t.co/EXRDKv0Y4H (@chulkimMD)
    MET (MET proto-oncogene, receptor tyrosine kinase) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    MET amplification
    over2years
    Discussing impact of met amplified patients in #lungcancer . May set us up for the next wave of new drugs says ⁦@benlevylungdoc⁩ with chair ⁦@StephenVLiu⁩ ⁦@OncLiveSOSS⁩ ⁦@LombardiCancer⁩ ⁦@HopkinsMedicine⁩ #ipc (@donnashort)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    over2years
    Escalation explored q2w & q3w at various doses. Expansion focused on pts with NSCLC and #MET amplification, exon 14 mutation, or protein expression (H-score ≥150). Included 52 pts with NSCLC and 40 were evaluable with a #MET H-score ≥150. Of these, 2 MET amp, 1 METex14, 2 #EGFR (@StephenVLiu)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation
    over2years
    Why is re-biopsy imp to patients? Why use Comprehensive Genomic Profiling with Hybrid based capture? MET is a detected acquired resistance in NSCLC fusions post Targeted Therapies (67% Amplification, 16% MET Exon 14). We need combo's post Lorlatanib #WCLC21 #LCSM @oncoOuLungCA (@livinglife82)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation
    over2years
    Also MET (amplification and/or mutation) is an acquired mechanism of resistance to EGFR⛔️. Have to rely on repeat tissue or #ctDNA. Otherwise you’ll miss these actionable findings. Many #clinicaltrials with MET⛔️ enrolling. #CRCSM #ESOCSM #STCSM https://t.co/j17tPnnwmV (@pashtoonkasi)
    Clinical • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification
    over2years
    From the archives by Dr. @LeciaSequist - Combination osimertinib + savolitinib has acceptable risk-benefit profile and encouraging antitumour activity in patients with MET-amplified, EGFR+, advanced NSCLC, who had disease progression on a previous EGFR TKI https://t.co/aySVrKozhI (@MGHThoracicOnc)
    Clinical • Benefit-risk assessment
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib)
    almost3years
    MET amplification as driver for some non-small cell lung cancers https://t.co/9Dk1i7azb9 (@weldeiry)
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    almost3years
    Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET–positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib @JTOonline https://t.co/ZCmqRnarbu (@VivekSubbiah)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • KIF5B (Kinesin Family Member 5B)
    |
    MET amplification • MET D1228N • MET fusion
    |
    Retevmo (selpercatinib) • Tabrecta (capmatinib)
    almost3years
    ⭐️Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET–positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib @JTOonline @oncoOuLungCA https://t.co/PoShj6K8vu (@VivekSubbiah)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • KIF5B (Kinesin Family Member 5B)
    |
    MET amplification • MET D1228N • MET fusion
    |
    Retevmo (selpercatinib) • Tabrecta (capmatinib)
    almost3years
    In depth discussion of NSCLC biomarker testing by Dr. @TejasPatilMD. Growing number of approved targeted agents; critical to understand granularity of testing (like what is high #MET amplification?) - nice primer for those in training or new to molecular pathology! @btfoundation (@StephenVLiu)
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification